Patent term restoration lets pharmaceutical companies recover time lost during FDA approval, extending drug exclusivity by up to five years. Learn how the Hatch-Waxman Act works, who qualifies, and why it's critical for drug innovation.
Between 2023 and 2025, patent lawsuits have become the main reason generic drugs are approved but never reach pharmacies. Patients pay thousands more each month while brand companies extend monopolies through legal tactics.